High prevalence of coagulation disorders, aging population, rising awareness about the available healthcare treatment options in emerging economies of Asia Pacific and Latin America and elevating healthcare spending in concurrence with GDP of the countries in these regions are the major factors which are expected to fuel the anticoagulants market globally.
Anticoagulants being the major part of the first line treatment of heart diseases including atrial fibrillation, deep vein thrombosis, pulmonary embolism, and stroke have been used extensively across the globe. Launch of four patented drugs in the market in newly formed anticoagulants drug class, novel oral anticoagulants (NOACs) in between 2008 and 2014 has resulted in revolutionary growth of the market as NOACs as they are very effective in preventing coagulation. Moreover, flexibility to consume the drugs orally in comparison to injectables and advantages such as less or single time requirement for blood test with use of NOACs over heparin is also favoring the segment in its growth.
Rivaroxaban, Apixaban, Dabigatran Etexilate and Edoxaban are the four major drugs which form the segment NOACs. Among these, Rivoroxaban dominated the global NOACs market in 2015 owing to the advantage of being oldest type of novel oral anticoagulant in the market. Additionally, advantage of one daily dose in case of rivaroxaban increased the demand for the drug among the patients, hence generating revenue for the segment. Apixaban is other major drug which is gaining demand in the market at high pace. Efficacy of apixaban to reduce mortality rate and major bleeding during its mechanism compared to other NOACs is the major factor which has helped the segment in gaining respective share in the market.
In 2015, on the basis of type, Heparin dominated the anticoagulants market. Application of the heparin in wide therapeutic indications including venous thromboembolism, extracorporeal circuit procedure, and treatment of disseminated intravascular coagulation is the major factor which has led to the domination of heparin in the market. NOACs segment followed the heparin market in the global anticoagulants market and is also estimated as the fastest growing segment in the market. Flexibility to consume the drugs orally in comparison to injectables coupled with the presence of patented drugs in the market is the major factor which has driven the market for NOACs globally.
The report titled “Global Anticoagulants Market Outlook to 2020 – Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market” provides a comprehensive analysis of the anticoagulants market. The report includes the cumulative revenue generated by the market players from the sales of anticoagulants, including both generic and patented drugs at manufacturer’s price and market share contributed by the sales of heparin, NOACs, Vitamin K Antagonists, and Injectable Direct Inhibitors in the total anticoagulants market. Further, the market in the study is differentiated on the basis of route of administration into oral and injectable. The market is also segmented by four geographical regions across the globe – North America, Europe, Asia Pacific, and Rest of the World. The stakeholders of this report includes the anticoagulants market players, wholesalers, group purchasing organizations, companies involved in research and development activities, and the new entrant who wish to invest in anticoagulants market in future.